Zhejiang Huahai Pharmaceutical (600521) Q4 2024 earnings summary

Executive summary

• Achieved revenue of ¥9.55 billion, up 14.91% year-over-year; net profit attributable to shareholders was ¥1.12 billion, up 34.74% year-over-year; adjusted net profit (excluding non-recurring items) was ¥1.13 billion, up 27.10% year-over-year.

• Growth driven by expanded sales scale, organizational restructuring, new product launches, and improved market share, with cost control and product mix optimization boosting gross margin and profitability.

• Cash flow from operations was ¥2.17 billion, and total assets reached ¥20.26 billion at year-end.

Financial highlights

• Revenue: ¥9.55 billion, up 14.91% year-over-year.

• Net profit attributable to shareholders: ¥1.12 billion, up 34.74% year-over-year.

• Adjusted net profit: ¥1.13 billion, up 27.10% year-over-year.

• Basic and diluted EPS: ¥0.77, up 35.09% year-over-year.

• Gross margin: 62.08%, up 1.53 percentage points year-over-year.

• Cash flow from operations: ¥2.17 billion.

Outlook and guidance

• 2025 sales revenue target set at ¥10.5 billion.

• Focus on expanding global sales, accelerating new product launches, and strengthening R&D in innovative and biological drugs.

• Continued emphasis on cost control, supply chain optimization, and compliance with evolving regulatory and environmental standards.